MAMohadeseh Arabhalvaei

Mohadeseh Arabhalvaei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohadeseh Arabhalvaei has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exploring the anticancer potential of epigallocatechin gallate-loaded sodium alginate nanoparticles: impact of size variation on head and neck cancer cells

    by Faezeh Rajabzadeh, Mohadeseh Arabhalvaei, Samaneh Arab, Elham Sadat Afraz, Marjan Bahraminasab

    Introduction Head and neck cancer is a common malignancy, and its current treatments face major challenges, including recurrence, drug resistance, side effects, and high costs. Epigallocatechin gallate (EGCG) from green tea has anticancer properties, but its low stability and bioavailability limit its clinical use. These limitations may be addressed by nanocarrier-based delivery systems. Methods Five different sizes of sodium alginate (SA) nanoparticles (NPs) were synthesized, and EGCG was loaded into the selected particles. Characterizations of SA NPs with and without EGCG were conducted using dynamic light scattering (DLS), field emission scanning electron microscopy (FE-SEM), and Fourier transform infrared spectroscopy (FTIR). Furthermore, loading capacity, entrapment efficiency, and release profile of the EGCG-loaded NPs were evaluated. The cytotoxicity and cell viability were assessed (MTT and LDH) on TSCC-1 cancer cells. Moreover, cellular uptake, wound healing, colony formation, and apoptosis were also tested. Results The characterizations of NPs confirmed the successful synthesis of SA NPs. Two NP sizes (type 1 and type 4) were selected for EGCG loading, for which the drug release was around 39% for type 1 and 51% for type 4 NPs after 14 days. The optimal cytotoxicity on cancer cells was observed at a concentration of 80 µg/mL of NPs (type 1). A significant reduction in colony numbers was observed after treatment with these EGCG-loaded NPs compared to controls. Furthermore, the EGCG-loaded NPs could prevent cancer cell migration, with an increase in apoptosis levels in TSCC-1 cells treated with type 1 NPs (80 µg/mL). Conclusion It was demonstrated that EGCG-loaded SA NPs effectively inhibit the proliferation and migration and induce apoptosis in head and neck cancer cells. Graphical abstract

  • In vitro anticancer effect of epigallocatechin gallate nano-emulsion on head and neck cancers

    by Zahra Khatib Zadeh, Samaneh Arab, Sohrab Kazemi, Mohadeseh Arabhalvaei, Elham Sadat Afraz, Marjan Bahraminasab

    Head and neck cancer, as one of the most common cancers, causes the death of many people worldwide every year. The current approaches to treat this cancer have not been successful, and recurrence, drug-resistance development, side effects, and high treatment costs are important problems necessitating the need for more effective drugs and treatment approaches. Epigallocatechin gallate (EGCG) is the most plentiful and biological-active catechin in green tea with proved anticancer effect. However, the stability, low bioavailability, and short half-life, limits its clinical use. Nanocarrier development may overcome these deficiencies by improving pharmacokinetics and pharmacodynamics. Therefore, this study aimed to examine the nano-emulsion containing EGCG for their anticancer activity. First, EGCG nano-emulsion was prepared, which was then characterized by dynamic light scattering (DLS), zeta potential, and Fourier transform infrared spectroscopy (FTIR). The toxicity of the nano-emulsion on the TSCC-1 cancer cell line was assessed by MTT and LDH assays. Cell migration rate, colony-formation ability, the apoptosis rate, and the expression level of BAX, BCL2, and VEGF genes after treatment of cancer cells were assessed. Moreover, the effect of EGCG nano-emulsion on the spheroid growth of TSCC-1 cells in three-dimensional (3D) culture was investigated. The FTIR results demonstrated the presence of EGCG in the nano-emulsion. The size and zeta potential of the nano-emulsion with and without EGCG were 17.53 ± 1.62 nm and − 0.166 ± 0.169 mV, and 14.0 ± 2.3 nm and − 0.266 ± 0.169 mV, respectively. The sustained drug release was observed. Moreover, the MTT assay exhibited that the cytotoxicity of the nano-emulsion was significant at a concentration of 80 µg/mL on TSCC-1 cells. The colony-formation assay revealed no colonies in the groups treated with nano-emulsion containing EGCG compared to the control group. The scratch test also showed the ability of nano-emulsion to inhibit cell migration. Furthermore, the induction of delayed apoptosis by 88.3 ± 3.18% was observed in the group treated with EGCG nano-emulsion at a concentration of 80 µg/mL. The expression of BCL2 and VEGF genes significantly decreased, while that of BAX gene increased. Moreover, the 3D culture showed a decrease in the size and growth of spheroids in the EGCG nano-emulsion-treated group compared to the control group. The results showed that the nano-emulsion containing EGCG has significant anticancer activity (TSCC-1) and may be a suitable treatment option for the management of squamous cell carcinoma of the head and neck. Graphical abstract


  • Open Access

    Exploring the Anticancer Potential of Epigallocatechin Gallate Loaded Sodium Alginate Nanoparticles: Impact of Size Variation on Head and Neck Cancer Cells

    by Faezeh Rajabzadeh, Mohadeseh Arabhalvaei, Samaneh Arab, Elham Sadat Afraz, Marjan Bahraminasab

    Head and neck cancers, particularly squamous cell carcinomas, are challenging to treat due to recurrence, drug resistance, and side effects. The present study explores using epigallocatechin gallate (EGCG), an anti-cancer compound from green tea, encapsulated in sodium alginate nanoparticles (SA NPs) of varying sizes. Five different sizes of SA NPs were synthesized, and EGCG was loaded into the selected particles. Characterizations of SA NPs with and without EGCG were conducted using dynamic light scattering (DLS), FE-SEM, and Fourier transform infrared spectroscopy (FTIR). Furthermore, the loading capacity, entrapment efficiency and release profile of the EGCG-loaded NPs were evaluated. The cytotoxicity and cell viability were assessed using MTT and LDH assays on TSCC-1 cancer cells. Moreover, cellular uptake, wound healing, colony formation and apoptosis were also tested. The results of characterizations confirmed the successful synthesis of SA NPs. Two NP sizes (type 1 and type 4) were selected for EGCG loading, for which the drug release was around 39% for type 1 and 51% for type 4 nanoparticles after 14 days. The optimal cytotoxicity on cancer cells was observed at a concentration of 80 µg/mL of NPs (type 1). The colony formation analysis displayed a significant reduction in colony numbers after treatment with EGCG-loaded NPs compared to controls. Furthermore, wound healing assays showed the ability of EGCG-loaded NPs to prevent cancer cell migration, and the evaluation of apoptosis demonstrated an obvious increase in apoptosis levels in TSCC-1 cells treated with type 1 NPs (80 µg/mL). It was demonstrated that EGCG-loaded SA NPs effectively inhibit the proliferation and migration, and induce apoptosis in head and neck cancer cells.